Abstract:In vitro-in vivo extrapolation (IVIVE) allows prediction of clinical outcomes across populations from in vitro data using specific scalars tailored to the biological characteristics of each population. This study experimentally determined scalars for patients with varying degrees of non-alcoholic fatty liver disease (NAFLD), ranging from fatty liver to non-alcoholic steatohepatitis (NASH) and cirrhosis. Microsomal, S9 and cytosol fractions were extracted from 36 histologically normal and 66 NAFLD livers (27 NAFL, 13 NASH, and 26 NASH with cirrhosis). Corrected microsomal protein per gram liver (MPPGL) progressively decreased with disease severity (27.2, 28.6, 24.5 mg/g in NAFL, NASH, and NASH/cirrhosis, respectively, compared with 37.2 mg/g in normal livers; ANOVA, p < 0.001). Homogenate, S9 and cytosolic protein showed a consistent trend of decline in NASH/cirrhosis relative to normal control (post-hoc <i>t</i>-test, p < 0.05). No differences across the groups were observed in homogenate, S9, cytosolic and microsomal protein content in matched kidney samples. MPPGL-based scalars that combine protein content with liver size revealed that the reduction in MPPGL in NAFL and NASH was compensated by the reported increase in liver size (relative scalar ratios of 0.94 and 0.99, respectively), which was not the case with NASH/cirrhosis (ratio of 0.61), compared with healthy control. PBPK-informed Global sensitivity analysis (GSA) of the relative contribution of IVIVE scalars (hepatic CYP3A4 abundance, MPPGL, liver size) to variability in exposure (AUC) to three CYP3A substrates (alprazolam, midazolam, ibrutinib) revealed enzyme abundance as the most significant parameter, followed by MPPGL, while liver volume was the least impactful factor. <b>Significance Statement</b> NAFLD-specific scalars necessary for extrapolation from microsomal or cytosolic in vitro systems to liver tissue are lacking. These scalars are required in clearance prediction and dose selection in NAFL and NASH populations. Reported disease-driven changes have focused on cirrhotic livers, with no data on the initial stages of liver disease. We obtained experimental values for microsomal, cytosolic and S9 fractions and assessed the relative impact of microsomal scalars on predicted exposure to different substrate drugs using physiologically based pharmacokinetics.

Toward a new paradigm for the efficient in vitro–in vivo extrapolation of metabolic clearance in humans from hepatocyte data

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

Prediction of Hepatic Plasma Clearance in Vivo from Gel-Entrapped Rat and Human Hepatocytes.

A 20-Year Research Overview: Quantitative Prediction of Hepatic Clearance Using the In Vitro-In Vivo Extrapolation Approach Based on Physiologically Based Pharmacokinetic Modeling and Extended Clearance Concept

[Advances and Related Issues in the Use of in Vitro Methods to Predict Metabolic Clearance Rate of New Drugs].

Improving In Vitro-In Vivo Extrapolation (IVIVE) of Clearance Using Rat Liver Microsomes for Highly Plasma Protein Bound Molecules

The potential protein-mediated hepatic uptake: discussion on the molecular interactions between albumin and the hepatocyte cell surface and their implications for the in vitro-to-in vivo extrapolations of hepatic clearance of drugs

In Vitro to In Vivo Scalars for Drug Clearance in Non-Alcoholic Fatty Liver and Steatohepatitis

How to Choose in Vitro Systems to Predict in Vivo Drug Clearance: A System Pharmacology Perspective.

Use of Segregated Hepatocyte Scaling Factors and Cross-Species Relationships to Resolve Clearance Dependence in the Prediction of Human Hepatic Clearance

An Investigation into the Prediction of the Plasma Concentration-Time Profile and Its Interindividual Variability for a Range of Flavin-Containing Monooxygenase Substrates Using a Physiologically Based Pharmacokinetic Modeling Approach

Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device

Cell cultures in drug discovery and development: The need of reliable in vitro-in vivo extrapolation for pharmacodynamics and pharmacokinetics assessment

Approach for extrapolating in vitro metabolism data to refine bioconcentration factor estimates

Development of novel tools for the in vitro investigation of drug-induced liver injury

Application of a New Dynamic Model to Predict the in Vitro Intrinsic Clearance of Tolbutamide Using Rat Microsomes Encapsulated in a Fab Hydrogel

In vitro to in vivo extrapolation methods in chemical hazard identification and risk assessment

Novel in vitro dynamic metabolic system for predicting the human pharmacokinetics of tolbutamide

Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance

Application of New Cellular and Microphysiological Systems to Drug Metabolism Optimization and Their Positioning Respective to In Silico Tools

Usage of In Vitro Metabolism Data for Drug‐Drug Interaction in Physiologically Based Pharmacokinetic Analysis Submissions to the US Food and Drug Administration